Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2021
Event: Disclosure of the closing of a registered direct offering previously announced on September 28, 2021.
Key Financial Metrics
This filing serves as a regulatory disclosure of a corporate event and does not contain audited financial statements, revenue figures, profit margins, cash flow data, or debt levels. Specific financial metrics regarding the offering (e.g., total proceeds, share price) are referenced in an attached press release (Exhibit 99.1) but are not detailed within the text of this Form 8-K.
Material Changes
The material change reported is the finalization of a registered direct offering. No comparative financial data or changes in operational metrics versus prior periods are provided in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the offering but contains no forward-looking guidance, strategic outlook, or management discussion beyond the event itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this report. The document includes standard disclaimers stating that the information in Item 7.01 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the number of shares sold, price per share, and total gross proceeds from the registered direct offering.
- Verify the impact of the new share issuance on existing shareholder dilution.
- Confirm the intended use of proceeds as outlined in the accompanying press release.
- Check subsequent filings for updated capitalization tables reflecting the new equity structure.